Andrew Tsai
Stock Analyst at Jefferies
(1.12)
# 3,390
Out of 5,090 analysts
27
Total ratings
36.36%
Success rate
-10.21%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MPLT MapLight Therapeutics | Initiates: Buy | $32 | $18.49 | +73.07% | 1 | Nov 21, 2025 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $25 | $13.43 | +86.15% | 2 | Nov 12, 2025 | |
| AVDL Avadel Pharmaceuticals | Downgrades: Hold | $22 → $20 | $21.34 | -6.28% | 1 | Oct 22, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $300 | $247.99 | +20.97% | 1 | Oct 16, 2025 | |
| AKRO Akero Therapeutics | Downgrades: Hold | $75 → $56 | $54.55 | +2.66% | 1 | Oct 9, 2025 | |
| BIIB Biogen | Initiates: Buy | $190 | $181.30 | +4.80% | 1 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $22.26 | +57.23% | 3 | Jul 24, 2025 | |
| STOK Stoke Therapeutics | Initiates: Buy | $30 | $30.87 | -2.82% | 1 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Buy | $70 | $73.64 | -4.94% | 1 | Jul 14, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Hold | $29 → $2.5 | $3.32 | -24.70% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $149.22 | +34.03% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $27 | $17.18 | +57.16% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $3.5 → $13 | $4.24 | +206.60% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $29.50 | +18.64% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $0.2 → $15 | $4.33 | +246.42% | 2 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.40 | +114.29% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $320 → $30 | $3.90 | +669.23% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $4.32 | +525.00% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $45.01 | -48.90% | 1 | Jun 1, 2020 |
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $32
Current: $18.49
Upside: +73.07%
Alto Neuroscience
Nov 12, 2025
Maintains: Buy
Price Target: $15 → $25
Current: $13.43
Upside: +86.15%
Avadel Pharmaceuticals
Oct 22, 2025
Downgrades: Hold
Price Target: $22 → $20
Current: $21.34
Upside: -6.28%
Praxis Precision Medicines
Oct 16, 2025
Maintains: Buy
Price Target: $65 → $300
Current: $247.99
Upside: +20.97%
Akero Therapeutics
Oct 9, 2025
Downgrades: Hold
Price Target: $75 → $56
Current: $54.55
Upside: +2.66%
Biogen
Sep 25, 2025
Initiates: Buy
Price Target: $190
Current: $181.30
Upside: +4.80%
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $22.26
Upside: +57.23%
Stoke Therapeutics
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $30.87
Upside: -2.82%
BridgeBio Pharma
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $73.64
Upside: -4.94%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $3.32
Upside: -24.70%
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $149.22
Upside: +34.03%
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $17.18
Upside: +57.16%
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $4.24
Upside: +206.60%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $29.50
Upside: +18.64%
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $4.33
Upside: +246.42%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.40
Upside: +114.29%
Jun 23, 2022
Downgrades: Hold
Price Target: $320 → $30
Current: $3.90
Upside: +669.23%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $4.32
Upside: +525.00%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $45.01
Upside: -48.90%